-+ 0.00%
-+ 0.00%
-+ 0.00%

Akari Therapeutics participates in Virtual Investor “Why Now” on-demand conference webcast

PUBT·08/27/2026 13:02:45
Listen to the news
Akari Therapeutics participates in Virtual Investor “Why Now” on-demand conference webcast
  • Akari Therapeutics participated in the Virtual Investor “Why Now” on-demand conference.
  • CEO Abizer Gaslightwala outlined an investment thesis tied to rising demand for differentiated ADC payload technologies.
  • Presentation emphasized the company’s PH1 RNA-splicing payload platform as a potential alternative to conventional ADC payloads.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270901PRIMZONEFULLFEED9816849) on August 27, 2026, and is solely responsible for the information contained therein.